Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

ABBVIE, LDA

NIF 510229050
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €7,125,089 65 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €7,125,089 65 contracts
A2 · Late Publication €14,991,522,363 3,288 contracts
Contract published to BASE more than 10 days after the signing date
LOW €14,991,522,363 3,288 contracts
A5 · Threshold Splitting €20,890,047 205 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €20,890,047 205 contracts
A6 · Low Competition €6,149,428 55 contracts
Only one bidder participated in a competitive procedure
MEDIUM €6,149,428 55 contracts
A9 · Price Overrun €27,187 1 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
HIGH €27,187 1 contracts
A9 · Abnormal Price Reduction €18,573,654,243 1,503 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €18,573,654,243 1,503 contracts
C3 · Missing Mandatory Fields €10,925,430 99 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €10,925,430 99 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

333
€720,560,755
160
€715,003,390
76
€699,740,983
58
€672,102,082
77
€653,503,769
190
€641,393,802
66
€637,691,765
43
€633,136,345
33
€613,211,255
480
€610,200,235
168
€605,092,562
82
€602,138,110
42
€584,982,415
212
€580,824,017
37
€575,524,525
150
€567,225,194
252
€556,074,813
121
€543,555,653
32
€526,670,650
122
€512,750,093
Page 1 of 3 · 59 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Price Overrun A9 · Abnormal Price Reduction C3 · Missing Mandatory Fields

Page 1 of 2 · 65 contracts

Aquisição Medicamentos Hepatite C_ Tratamento 8 semanas
PT · 12234554 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€5,500 2025-12-24
Aquisição do medicamento Mirvetuximab soravtansina 5 mg/ml Sol inj Fr 20 ml IV - AE
PT · 11991848 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€31,554 2025-11-15
AQUISIÇÃO URGENTE DE VARIOS MEDICAMENTOS
PT · 11978826 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€68,900 2025-09-30
ADALIMUMAB [40 MG; SOL INJ; FRS/ SER/ CANETA].
PT · 11714134 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€14,095 2025-09-11
AQ. URGENTE DIVERSOS MEDICAMENTOS
PT · 11986613 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€78,851 2025-09-02
AQ. URGENTE DIVERSOS MEDICAMENTOS
PT · 11957754 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€20,083 2025-07-15
Aquisição medicamento risancizumab cartucho 360mg/2.4ml sc_risancizumab inj. 600mg/10ml iv
PT · 11484899 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€11,062 2025-05-23
Aquisição medicamento foslevodopa + foscarbidopa inj. 2400+120mg/10ml sc
PT · 11483651 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€25,622 2025-03-27
VÁRIOS MEDICAMENTOS
PT · 11315143 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€43,093 2025-03-25
Aquisição medicamentos epcoritamab inj. 4mg/0.8ml sc_epcoritamab inj. 48mg/0.8ml sc
PT · 11464655 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€92,250 2025-02-03
MEDICAMENTOS
PT · 11144457 · Ajuste Direto Regime G...
A1 · Repeat Direct Award C3 · Missing Mandatory Fields
€179,172 2024-12-10
Aquisição de ADALImumab 40 mg/0.4 ml Sol inj Caneta 0.4 ml SC - Abbvie
PT · 11067757 · Ajuste Direto Regime G...
A5 · Threshold Splitting A1 · Repeat Direct Award +1
€19,200 2024-12-05
Medicamento Adalimumab - Canetas
PT · 10849850 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€432,000 2024-02-01
VÁRIOS MEDICAMENTOS
PT · 10560881 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€252,544 2024-01-19
Medicamento Adalimumab 20mg/0,2ml
PT · 10313512 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€0 2023-10-23
Medicamento Adalimumab 80mg/0.8ml
PT · 10331939 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€0 2023-10-12
VÁRIOS MEDICAMENTOS
PT · 10246961 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€16,429 2023-08-29
Medicamento Adalimumab 80 mg_ doentes em tratamento
PT · 10076668 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€48,968 2023-05-17
Vários Medicamentos
PT · 9854020 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€77,288 2023-03-02
Vários Medicamentos
PT · 9781208 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€120,269 2023-01-19
Vários Medicamentos
PT · 9617648 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€267,623 2022-12-12
Vários Medicamentos
PT · 9626916 · Ajuste Direto Regime G...
A5 · Threshold Splitting A1 · Repeat Direct Award +1
€72,294 2022-12-05
vários medicamentos
PT · 9397449 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€8,380 2022-08-02
Vários medicamentos
PT · 9035077 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€31,108 2022-02-23
AD 730-2020 Aquisição de Venetoclax 100 mg Comp.
PT · 7111445 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€124,411 2020-03-27
Aquisição de Venetoclax (10 mg-50 mg-100 mg) Comp
PT · 6969041 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€62,813 2019-08-27
OUTROS ANTIRETROVIRAIS
PT · 4563728 · Ajuste Direto Regime G...
A5 · Threshold Splitting A1 · Repeat Direct Award +1
€145,788 2018-02-15
Adalimumab 40 mg/0.4 ml Sol inj Caneta 0.4 ml SC
PT · 4516057 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€318,028 2017-03-17
ANESTESICOS GERAIS E LOCAIS
PT · 3255114 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€158,394 2017-02-23
51000117 - MEDICAMENTOS C/ CHNM
PT · 4072803 · Ajuste Direto Regime G...
A5 · Threshold Splitting A1 · Repeat Direct Award +2
€74,123 2017-01-16
Aquisição de medicamentos
PT · 2853823 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€38,004 2016-09-06
Aquisição de medicamentos
PT · 2868690 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€66,654 2016-01-15
Medicamentos do foro oncológico - com base no CPA 2013/6
PT · 2276080 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€0 2015-10-29
Aquisição de medicamentos do Foro Oncológico
PT · 2061048 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€1,566 2015-10-29
Aquisição de medicamentos c/CHNM do catálogo
PT · 2060890 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€629 2015-09-17
Aqquisição de medicamentos do Foro Oncológico
PT · 1363574 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A9 · Abnormal Price Reduction
€4,416 2015-01-21
Aquisição de medicamentos c/CHNM do catálogo
PT · 1721363 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€381 2014-11-07
Aquisição de medicamentos c/CHNM do catálogo
PT · 1721246 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€1,450 2014-10-16
Aquisição de medicamentos c/CHNM do catálogo
PT · 1720634 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€875 2014-07-03
Aquisição de medicamentos c/CHNM do catálogo
PT · 1719038 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€1,704 2014-03-28
5410540/2014 - Anestesicos e relaxantes musculares
PT · 1642629 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€0 2014-03-06
Aquisição de medicamentos c/CHNM do catálogo
PT · 1625566 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€1,591 2014-02-24
Aquisição de medicamentos c/CHNM do catálogo
PT · 1625189 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€2,195 2014-02-21
MEDICAMENTOS PARICALCITOL 1MG
PT · 810546 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€0 2013-04-30
MEDICAMENTOS PALIVIZUMAB 100MG
PT · 809224 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€0 2013-04-30
Medicamentos "Lopinavir+Ritonavir Sol. Oral e Ritonavir 100mg
PT · 794943 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€127,872 2013-02-08
MEDICAMENTOS SEVOFLURANO
PT · 820296 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€0 2013-01-24
Medicamentos Lopinavir + Ritonavir
PT · 682164 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€621,172 2013-01-22
Medicamento Adalimumab349
PT · 682139 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€696,738 2013-01-16
Aquisição de medicamentos varios em CPA
PT · 730309 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€205,000 2012-12-03
Next →
Overview
Total Value Won
€18,846,490,806
Contracts Won
4,728
Score 160085 · CRITICAL RISK
NIF
510229050
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

  • C.P. [P-93b9]
    Gerente
    since 2017-09-06
  • C.M. [P-a59e]
    Gerente
    since 2019-10-03
  • C.M. [P-a59e]
    Gerente
    since 2022-07-11
  • C.M. [P-a59e]
    Gerente
    since 2025-07-08
  • C.R. [P-5fd1]
    Gerente
    since 2020-02-19
  • F.V. [P-260a]
    Gerente
    since 2013-01-03
  • G.G. [P-b5cc]
    Gerente
    since 2023-03-31
  • G.G. [P-b5cc]
    Gerente
    since 2025-07-08
  • L.C. [P-dfea]
    Gerente
    since 2023-09-27
  • M.I. [P-bb79]
    Gerente
    since 2015-06-11
  • N.G. [P-e1e3]
    Gerente
    since 2026-04-08
  • O.M. [P-8e9a]
    Gerente
    since 2022-07-11
  • R.A. [P-6f67]
    Gerente
    since 2019-04-30
  • W.J. [P-08cb]
    Gerente
    since 2013-01-03
  • A.A. [P-0394]
    Sócio
    since 2012-04-05
  • A.A. [P-0394]
    Sócio
    since 2012-08-01
  • A.S. [P-ec2b]
    Sócio
    since 2012-04-05
  • A.S. [P-ec2b]
    Sócio
    since 2012-08-01
  • A.C. [P-59a3]
    Sócio
    since 2021-07-05
  • A.S. [P-f521]
    Sócio
    since 2021-07-05
  • A.D. [P-368d]
    Gerente
    2022-07-11 → 2023-09-27
  • C.P. [P-93b9]
    Gerente
    2019-04-30 → 2020-02-19
  • C.R. [P-5fd1]
    Gerente
    2022-07-11 → 2023-03-31
  • E.L. [P-442d]
    Gerente
    2012-04-05 → 2015-04-13
  • F.A. [P-b4fa]
    Gerente
    2012-04-05 → 2013-01-03
  • F.V. [P-260a]
    Gerente
    2015-04-13 → 2015-06-04
  • K.K. [P-2ee1]
    Gerente
    2022-07-11 → 2025-01-06
  • L.C. [P-dfea]
    Gerente
    2025-07-08 → 2026-04-08
  • M.I. [P-bb79]
    Gerente
    2019-04-30 → 2019-10-03
  • O.M. [P-8e9a]
    Gerente
    2025-07-08 → 2026-03-30
  • R.J. [P-33a8]
    Gerente
    2015-04-13 → 2017-07-24
  • T.C. [P-d023]
    Gerente
    2012-04-05 → 2013-01-03
  • W.J. [P-08cb]
    Gerente
    2015-04-13 → 2019-04-30
Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned